Pafuramidine (DB289), 2,5-bis-(4-amidinophenyl)furan-bis-O-methylamidoxime, is a promising new orally active antiparasitic compound (9) . A recent clinical study found that pafuramidine (200 mg/kg of body weight/day for 5 days) was effective for 96% (22 of 23) of Plasmodium falciparum-infected patients (9) . In vivo, pafuramidine is metabolized into the active metabolite 2,5-bis-(4-amidinophenyl)furan (DB75) (10, 11) . Previous studies have shown that DB75 is effective against P. falciparum, Plasmodium vivax, Pneumocystis jirovecii, Trypanosoma brucei, and Leishmania spp. in vitro and in animal models (2, 7) .
Currently, the WHO recommends that all new antimalarial drugs be used in combination with a second antimalarial drug to prevent the development of resistance to monotherapy. The two partnered drugs cannot be antagonistic and should ideally be synergistic (8) . The purpose of this study was to characterize the interactions of the active metabolite of pafuramidine, DB75, with potential antimalarial partner drugs.
To measure in vitro drug sensitivity, we used 42-h microdilution checkerboard growth assays and cultured P. falciparum 3D7 parasites as previously described (4) . Serial dilutions of DB75 were tested in combination with serial dilutions of each partner drug: amodiaquine, artemisinin, atovaquone, azithromycin, chloroquine, clindamycin, mefloquine, piperaquine, pyronaridine, tafenoquine, and tetracycline (3). Drug concentrations ranged from 5-to 10-fold above and below the predetermined 50% inhibitory concentration (IC 50 ). For each partner drug, the assay was repeated two or three times. The atovaquone-proguanil combination was used to validate the method and to determine the threshold of the sum of fractional inhibitory concentrations (FIC) for synergism.
Additionally, 66-h and 96-h exposure periods were used for select drugs (tetracycline, clindamycin, azithromycin, and tafenoquine) with long onsets in vitro. To measure growth in 66 h, the methods described above were followed except that a 0.4% parasite population was used and [ 3 H]hypoxanthine was added for the final 18 h of incubation. Ring cultures synchronized with 0.3% sorbitol were used for the 96-h assay, and [
3 H]hypoxanthine was added for the final 48 h.
Results were expressed as FIC and as the mean sums of the FIC. DB75-partner drug interactions were defined as either indifferent (linear points on isobolograms; sum of FIC ϭ 1), synergistic (concave curves on isobolograms; sum of FIC ϭ Յ0.63) (atovaquone and proguanil), or antagonistic (convex curves on isobolograms; sum of FIC ϭ Ͼ2.0) (1, 3).
To find a potential partner for DB75, the compound was tested in combination with 11 current and investigational antimalarials. DB75 manifested indifferent relationships with 10 of the drugs tested in the 42-h assay by both the FIC and sum-of-FIC methods ( Fig. 1; Table 1 ). As a positive control, atovaquone and proguanil showed clear synergy (sum of FIC ϭ 0.63).
Three of these drugs (tetracycline, tafenoquine, and azithromcycin) also showed indifference even with extended incubations (Fig. 1F, D, and B, respectively; Table 1 ).
The clindamycin-DB75 combination was indifferent at 96 h ( Fig. 1L; Table 1 ). As previously reported, clindamycin alone exhibited a biphasic dose response by the 42-and 66-h assays (data not shown) (5). Complete inhibition was not achieved with clindamycin at these times, even with hemolytic concentrations greater than 100 M; therefore, no IC 50 could be extrapolated for the 42-or 66-h assay. However, at 96 h, a sigmoidal dose response was evident for clindamycin alone; therefore, an FIC could be determined. In summary, the lack of interaction of DB75 with either chloroquine or atovaquone suggests that DB75 does not interact with hemozoin or mitochondria in the parasite, as has been previously suggested (6) . These data also suggest that pafuramidine could be successfully partnered with any of the 11 antimalarials tested here. Follow-up studies in animal models are needed.
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